Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.46 |
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700886 | 0.92 | RIPK1 (0.47) | RIPK1BRAFHTR2AHTR7HTR6 | |
| SCHEMBL15053500 | 0.91 | BRAF (0.49) | RIPK1BRAFHTR2AHTR7HTR6 | |
| SCHEMBL15053280 | 0.90 | TRPV1 (0.44) | RIPK1BRAFHTR2AHTR7HTR6 | |
| SCHEMBL15052475 | 0.90 | HTR1A (0.40) | RIPK1BRAFHTR2AHTR7HTR6 | |
| SCHEMBL15053304 | 0.90 | BRAF (0.41) | BRAFHTR2AHTR7HTR6P2RY1 | |
| SCHEMBL15053740 | 0.89 | BRAF (0.48) | RIPK1BRAFKDR | |
| SCHEMBL15053384 | 0.89 | BRAF (0.41) | BRAFHTR2AHTR7KDR | |
| SCHEMBL15052967 | 0.89 | HTR2A (0.39) | RIPK1BRAFHTR2AHTR7HTR6 | |
| SCHEMBL15053139 | 0.89 | HTR1A (0.46) | BRAFHTR2AHTR7HTR6P2RY1 | |
| SCHEMBL15053552 | 0.87 | FGFR1 (0.41) | RIPK1BRAFHTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | RIPK1 438/4885BRAF 90/4885HTR2A 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.